Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Intravenous immunoglobulin (IVIg) therapy is widely used to treat a variety of autoimmune diseases including immunothrombocytopenia, chronic inflammatory demyelinating polyneuropathy, and more recently autoimmune skin blistering diseases. Despite this well‐documented clinical success, the precise molecular and cellular mechanisms underlying this immunomodulatory activity are discussed controversially. In particular, the clinically relevant therapeutic pathway of IVIg‐mediated immune modulation has not been studied in detail. In the present study, we use four independent in vivo model systems of auto‐Ab‐mediated autoimmune disease to identify a common pathway explaining IVIg activity under therapeutic conditions in vivo. We show that irrespective of the in vivo model system, IVIg activity is strictly dependent on the presence of terminal sialic acid residues and the inhibitory FcγRIIB under preventive as well as therapeutic treatment conditions. In contrast, specific ICAM3 grabbing nonintegrin related 1, previously demonstrated to be essential under preventative treatment conditions, showed a disease‐specific impact on IVIg‐mediated resolution of established autoimmune disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Self-citationRecapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc
Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C., & Ravetch, J. V. (2008) · Science · doi:10.1126/science.1154315 · Cited by 849
Self-citationInfusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura
Debré, M., Griscelli, C., Bonnet, M.-C., Carosella, E., Philippe, N., Reinert, P., Vilmer, E., Kaplan, C., Fridman, W. H., & Teillaud, J.-L. (1993) · The Lancet · doi:10.1016/0140-6736(93)92000-j · Cited by 329
Cited by
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
Type I and type II Fc receptors regulate innate and adaptive immunity
Pincetic, A., Bournazos, S., DiLillo, D. J., Maamary, J., Wang, T. T., Dahan, R., Fiebiger, B.-M., & Ravetch, J. V. (2014) · Nature Immunology · doi:10.1038/ni.2939 · Cited by 514
Mechanisms of Autoantibody-Induced Pathology
Ludwig, R. J., Vanhoorelbeke, K., Leypoldt, F., Kaya, Z., Bieber, K., McLachlan, S. M., Komorowski, L., Luo, J., Cabral-Marques, O., Hammers, C. M., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00603 · Cited by 469
Self-citationThe Emerging Importance of IgG Fab Glycosylation in Immunity
van de Bovenkamp, F. S., Hafkenscheid, L., Rispens, T., & Rombouts, Y. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502136 · Cited by 307
IVIG-mediated effector functions in autoimmune and inflammatory diseases
Galeotti, C., Kaveri, S. V., & Bayry, J. (2017) · International Immunology · doi:10.1093/intimm/dxx039 · Cited by 269
Metadata
- Authors
- Schwab, I., Mihai, S., Seeling, M., Kasperkiewicz, M., Ludwig, R. J., & Nimmerjahn, F.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2014-03-07
- Volume
- 44
- Issue
- 5
- Pages
- 1444-1453
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W1838834699
- Cited by
- 129
- References
- 3
- FWCI
- 13.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo. https://app.cochat.ai/papers/10.1002/eji.201344230
- The paper
- Schwab, I., Mihai, S., Seeling, M., Kasperkiewicz, M., Ludwig, R. J., & Nimmerjahn, F. (2014). Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo. European Journal of Immunology. https://doi.org/10.1002/eji.201344230
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.